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1. Introduction 
The pericardium is a biological tissue widely used as a biomaterial for tissue engineering 
applications, including the construction of a variety of bioprostheses such as vascular grafts, 
patches for abdominal or vaginal wall reparation and, more frequently, heart valves. 
However, despite significant advances, some drawbacks have been found in these 
bioprostheses such as biological matrix deterioration and tissue degeneration associated 
with calcifications, even though xenopericardium or glutaraldehyde-treated autologous 
pericardium were used. 
In non-autologous pericardial processing, the pericardium must be decellularized in order 
to remove cellular antigens and procalcific remnants while preserving extracellular matrix 
integrity. A large variety of decellularization protocols exist, such as chemical, physical or 
enzymatic methods. Additional cross-linking processing must be carried out to render the 
tissue non-antigenic and mechanically strong. 
So far, almost all bioprosthetic materials made of pericardium, and used in clinical practice, 
are glutaraldehyde-treated bovine or porcine xenopericardium. However, long-term reports 
are raising issues concerning their durability, especially highlighting the high risk of 
calcification. Regarding heart valves, calcification currently represents the major drawback 
leading to potential failure of the bioprosthesis.  
The aim of this review is to present current issues, challenges, outcomes and future 
prospects of pericardial processing, including decellularization and cross-linking steps. 
Understanding current issues and improving pericardial processing will allow refining 
bioprosthesis conception and patients’ safety. 
2. Characteristics of the pericardium 
2.1 Localization and composition 
The pericardium is a connective tissue sac surrounding the heart. It is composed by two 
layers: a deeper layer closely adherent to the heart, the visceral serous pericardium, or 
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epicardium, and an upper layer: the parietal pericardium. The two layers are separated by 
the pericardial cavity. The parietal pericardium can be excised and easily tested without 
causing major complications such as contracture or ischemia (Fomovsky et al., 2010).  
 
 
Fig. 1. Histology of ovine pericardium showing the collagen organization (arrows). 
Hematoxylin-Eosin staining. 
The pericardium is composed of a simple squamous epithelium and connective tissue. It is a 
collagen-rich biological tissue containing mostly type I collagen, as well as glycoproteins 
and glycosaminoglycans (GAGs) in addition to its constitutive cells (Figure 1). Collagen is 
structured into different levels of organization ranging from fibrils to laminates, fibers and 
fiber bundles (Allen & Didio, 1984; Lee & Boughner, 1981). This organization determines the 
mechanical properties of the pericardial tissue (Sacks, 2003; Liao et al., 2005; Wiegner & 
Bing, 1981; Lee & Boughner, 1985) and provides an anisotropic and non-linear mechanical 
behaviour (Zioupos & Barbenel, 1994). Interestingly, depending on the location on the 
pericardium, the thickness and mechanical properties vary (Hiester & Sacks 1998a, 1998b). 
Thus, the location of the sample that will be harvested should be carefully selected when 
designing a tissue engineering protocol. 
2.2 Sources of pericardium 
Currently marketed heart valve bioprostheses are prepared from bovine or porcine 
pericardium (Vesely, 2005). Other pericardial tissues from different species have been 
assessed or are currently used in clinical practice such as equine (DeCarbo et al., 2010; 
Yamamoto et al., 2009; Sato et al.; 2008.), canine (Lee & Boughner ; 1981; Wiegner & Bing, 
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1981; 1985), or, even more unusually, ostrich (Maestro et al., 2006) or kangaroo pericardium 
(Neethling et al., 2000; 2002). However, those exogenous grafts raise several issues, and 
especially the immune response against the bioprosthesis as well as the viral status of the 
graft.  
Human autologous pericardium is thus an interesting option, presenting several advantages 
over allografts since it is free of donor-derived pathogens and does not induce any immune 
response (Mirsadraee et al., 2007), is easily available, easily handled and of low cost. 
Ultimately, these characteristics allow for shorter and less aggressive pericardial processing 
before implantation of the bioprosthesis. However, because of intermittent reports of its 
tendency to retract or become aneurysmal, the general opinion has been negative (Edwards 
et al., 1969, Bahnson et al., 1970). For cusp tissue replacement or valve tissue replacement, 
stabilization of pericardium is performed with a solution of 0,2% to 0,6% glutaraldehyde in 
order to prevent secondary shrinkage (Duran et al., 1998; Al-Halees et al., 1998, 2005; Goetz 
et al., 2002). 
3. Processing of pericardium 
As allografts have been the main source for pericardial bioprostheses currently in use, 
significant processing steps have to be performed prior to clinical use. In particular, as 
xenogeneic cellular antigens induce an immune response or an immune-mediated rejection 
of the tissue, decellularization protocols are widely used to reduce the host tissue response 
(Gilbert et al., 2006.). Once decellularized, the free-cell pericardial tissue is composed of 
extracellular matrix proteins which are generally conserved among species, and thus can be 
easily used as a scaffold for the host cell attachment, migration and proliferation (Schmidt & 
Baier, 2000). This scaffold considerably accelerates tissue regeneration. Overall, tissue 
decellularization aims at reducing tissue antigenicity and host response while preserving 
the mechanical integrity, biological activity and composition of the ECM (Simon et al., 2006; 
Gilbert et al., 2006). 
3.1 Extracellular matrix decellularization methods 
Most decellularization protocols include a combination of various methods, such as 
physical, enzymatic or chemical treatments (Gilbert et al., 2006; Crapo et al., 2011). Physical 
methods can either rely on snap freezing (Jackson et al., 1988; Roberts et al., 1991), 
mechanical force (Freytes et al., 2004) or mechanical agitation (Schenke-Layland et al., 2003), 
whereas enzymatic protocols employ nucleases, calcium chelating agents or protease 
digestion (Teebken et al., 2000; Bader et al., 1998; McFetridge et al., 2004; Gamba et al., 2002).  
Regarding physical decellularization processes, sonication, based on the use of ultrasounds 
to disrupt the cell membrane, has been investigated. Such treatment considerably affects the 
pericardial architecture and full decellularization cannot be achieved. Thus sonication has to 
be carried out simultaneously with chemical treatments in order to fully decellularize the 
pericardial tissue and remove cellular debris. However, this combination leads to alterations 
of the extracellular matrix (ECM) architecture. 
For the enzymatic procedure, the main enzyme employed is trypsin, cleaving peptide 
bonds on the C-side of arginine and lysine and thus allowing separation of the cells from 
the ECM. 
Chemical protocols involve use of alkaline and acid treatments (Freytes et al., 2004), ionic 
detergents, sodium dodecyl sulfate (SDS), sodium deoxycholate and Triton X-200 (Rieder et 
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al. 2004; Hudson et al., 2004), non-ionic detergents, such as Triton X-100 (Grauss et al., 2003), 
zwitterionic detergents (Dahl et al., 2003), tri(n-butyl)phosphate (Woods & Gratzer, 2005) as 
well as hypertonic or hypotonic solutions (Goissis et al., 2000; Woods & Gratzer, 2005; 
Vyavahareet al., 1997; Dahl et al., 2003). These modalities will either mediate lysis of the cells 
or solubilization of the cellular components. 
Overall, standard decellularization protocols for allografts consist of a multimodal process 
starting with the lysis of the cell membrane using either ionic solutions or physical 
treatments. This initial step is then followed by enzymatic treatments to separate any 
cellular components from the ECM. Subsequently, detergents are used to solubilize the 
nuclear and cytoplasmic cellular components. At the end of the procedure, all residual cell 
debris is removed from the remaining ECM. A washing step must also be carried out 
following the decellularization protocol to remove residual chemicals, thus avoiding any 
host tissue response (Gilbert et al., 2006). The efficiency of the decellularization protocol and 
the preservation of the ECM have to be assessed using histological tools. 
Concerning pericardial decellularization, several protocols, which have provided interesting 
results, can be found in the literature. (Courtman et al., 2004; Liang et al., 2004; Wei et al., 2005; 
Chang et al., 2005; Mendoza-Novelo et al., 2010, Ariganello et al., 2011 ). Courtman et al. 
proposed the use of a non-ionic detergent, Triton X-100 and an enzymatic extraction process. 
After this treatment, the acellular matrix was shown to be composed of collagen, elastin and 
glycosaminoglycans (GAG). Microscopy revealed that all cellular components were removed 
and that matrix ultrastructure was intact. More recently, Mendoza-Novelo et al. compared the 
surfactant tridecyl alcohol ethoxylate (ATE) and the reversible alkaline swelling (RAS) 
treatments to Triton X-100 (Mendoza-Novelo et al., 2010 ). Histological results indicated a 
significant reduction of cellular antigens with these three decellularization processes. 
Nevertheless, the native GAG content varied significantly. It decreased from 88.6 ± 0.2% to 
62.7 ± 1.1% and 61.6 ± 0.6% for RAS treatment, ATE and Triton X-100 respectively. 
On human pericardial tissue, Mirsadraee et al. used a protocol employing hypotonic buffer, 
SDS, protease inhibitors and nuclease solution. Following decellularization, the tissue is 
decontaminated using a peracetic acid solution (Mirsadraee et al., 2006; 2007). With this 
process, glycosaminoglycans and structural proteins, such as collagen, remained intact.  
Finally, when dealing with autologous pericardium grafting, full decellularization might not 
be necessary and thus, simpler protocols can be used. For instance, surgeons commonly 
prepare autologous pericardium for heart valve replacement by mechanical friction. This 
allows removing sub-pericardial fat before implantation while better preserving the 
pericardial architecture stability. This mechanical treatment mainly removes superficial 
cells, thus allowing 50% of viable pericardial cells to remain in the graft (personal data). The 
preservation of the pericardial architecture as well as part of the pericardial cells, should 
maintain a better integrity of the graft, while allowing re-cellularization of the superficial 
layers. 
3.2 Effects of decellularization 
Depending on the protocol, decellularization may have an impact on the structural and 
mechanical properties of the treated tissue (Gilbert et al., 2006). According to Zhou et al., 
decellularization protocols differ significantly in terms of alteration of ECM 
histoarchitecture (Zhou et al., 2010). For instance, decellularization protocols have a strong 
impact on the amount of GAGs remaining in a tissue (Badylak et al., 2009; Mendoza-Novelo 
et al., 2010). Removing GAGs from a tissue leads to adverse effects on pericardial 
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viscoelastic properties. This can be easily understood since water retention is an important 
function of GAGs in tissues (Lovekamp et al., 2006). Moreover, GAG content plays a key 
biological role in cellular signaling and communication. Thus, decreasing GAG content 
leads to an impaired tissue response and repair. Therefore, the decellularization protocol has 
to be carefully chosen depending on the tissue type as well as the targeted application. 
Ideally, the process should remove all cellular antigens without compromising the structure 
and mechanical properties of the tissue. 
Liao et al. (Liao et al., 2008) investigated the effect of three decellularization protocols on the 
mechanical and structural properties on porcine aortic valve leaflets. These protocols were 
based on the use of SDS, Trypsin and Triton X-100. They showed that decellularization 
resulted in collagen network disruption, and that the ECM pore size varied as a function of 
the protocol used. For example, leaflets treated with SDS displayed a dense ECM network 
and small pore sizes, characteristics that may have an impact on the recolonization of 
interstitial cells. 
It has been demonstrated that decellularization of bovine pericardium with SDS causes 
irreversible denaturation, swelling and a decrease in tensile strength compared to native 
tissue (Courtman et al. 1994; García-Paéz et al., 2000; Mendoza-Novelo et al., 2009). Because 
of these deleterious effects on pericardial tissue, non-ionic detergents are preferred for 
decellularization processes (Mendoza-Novelo et al., 2010 ). Nevertheless, some issues may 
be encountered with the use of non-ionic detergents. Indeed, toxic effects (Argese et al., 
1994) and estrogenic effects (Soto et al., 1991; Jobling et al., 1993) have been reported after 
the use of non-ionic detergents such as alkylphenol ethoxylates.  
Decellularization mediates alterations of the structural and mechanical properties of the 
tissue, but this impact varies depending on the protocol used. For instance, Mirsadraee et al. 
(Mirsadraee et al., 2006) did not observe any significant changes using an SDS-based 
decellularization protocol in the ultimate tensile strength compared to native tissue on 
human pericardial tissue. They also observed an increased extensibility of the tissue when 
cut parallel to collagen bundles.  
Tissue decellularization reduces the cellular and humoral immune response targeted against 
the bioprosthesis (Meyer et al., 2005). However, removing cells does not ensure adequate 
removal of xenoantigens, nor mitigation of the immune response (Goncalves et al., 2005; 
Kasimir et al., 2006; Simon et al., 2003; Vesely et al., 1995). For this reason, decellularization 
protocols have turned to antigen removal protocols (Ueda et al., 2006; Kasimir et al., 2005). The 
presence of cell membrane antigens, such as oligosaccharide beta-Gal has been reported to 
lead to an immune response that can be prevented by effective decellularization (Badylak et 
al., 2008). Interestingly, Griffiths et al. (Griffiths et al., 2008) used an immunoproteomic 
approach to study the ability of bovine pericardium to generate a humoral immune response. 
They identified thirty one putative protein antigens. Some of them, such as albumin, 
hemoglobin chain A and beta hemoglobin have been identified as xenoantigens. Recently, 
Ariganello et al. provided evidence that decellularized bovine pericardium induced less 
differentiation of the monocytes to macrophages compared to polydimethylsiloxane or 
polystyrene surfaces (Ariganello et al., 2010; 2011). Nevertheless, the effects of the host 
immune response to acellular pericardium remain to be fully characterized. Understanding 
this phenomenon is necessary to develop new pericardium preparations and thus improve 
biological scaffold integration and clinical safety (Badylak & Gilbert, 2008). 
Overall, no optimal decellularization treatment has been identified so far, but depending on 
the target tissue as well as the implantation site, the protocol can be adapted to provide the 
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best decellularization efficiency / functional characteristics ratio. Moreover, some additional 
treatment can be performed following the decellularization step in order to improve the 
mechanical and biological features of the graft. 
4. Pericardial extracellular matrix treatment 
The decellularization process will lead to important alterations of the biomaterial. Its 
mechanical strength will be diminished and after implantation it will undergo rapid 
resorption. Hence, approximately 60% of the mass of the ECM is degraded and resorbed 
between one and three months after in vivo grafting (Badylak & Gilbert, 2008). It has also 
been noted that acellular pericardial tissue, mostly made of type I collagen, is highly 
thrombogenic (Keuren et al., 2004). Finally, preventing calcification of the graft is also a 
priority to ensure the long-term benefit of the implantation. 
To optimize the features of the bioprosthesis before its clinical grafting, several treatments 
have been developed and are summarized in Table 1. 
 
 Reagents References 
Cross-linking 
treatment 
Acyl azide (Petite et al., 1990) 
Carbodiimides (Sung et al., 2003) 
Cyanimide (Pereira et al., 1990) 
Dye-mediated photooxidation (Moore et al., 1994) 
Epoxy compound (Sung et al., 1997) 
Formaldehyde (Nimni et al, 1988) 
Genepin (Sung et al., 1999, 2003; Wei et al., 2005) 
Glutaraldehyde (Huang-Lee et al, 1990; Jayakrishnan et al., 
1996; Thubrikar et al., 1983) 
Glutaraldehyde acetals (Yoshioka et al., 2008) 
Penta-golloyl glucose (Tedder et al., 2008) 
Phytate (Grases et al., 2006, 2008) 
Proanthocyanidin (Han et al., 2003) 
Reuterin (Chen et al., 2002) 
Tannic acid (Cwalina et al., 2005; Jastrzebska et al., 2006;  
Wang et al., 2008) 
Coating 
treatment 
Chitosan (Nogueira et al., 2010) 
RGD polypeptides (Dong et al., 2009) 
Silk fibroin (Nogueira et al., 2010) 
Heparin sodium (Lee et al., 2000) 
Titanium (Guldner et al., 2009) 
Post-fixative 
treatment 
Amino acids (Jorge-Herrero et al., 1996;  
Moritz et al., 1991) 
Glycine (Lee et al., 2010) 
Heparin (Lee et al., 2000, 2001) 
Hyaluronic acid (Ohri et al., 2004) 
L-arginine (Jee et al., 2003) 
L-glutamic (Grimm et al., 1991; Leukauf et al., 1993) 
Lyophilization (Santibáñez-Salgado et al., 2010) 
Sulphonated poly(ethylene oxide) (Lee et al., 2001) 
Table 1. Pericardial processing. 
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4.1 Cross-linking treatment of pericardial tissue 
Cross-linking processing must be carried out to render the tissue non-antigenic, 
mechanically strong and to minimize xenogeneic tissue degradation (Eliezer et al., 2005; 
Love, 1997). Nevertheless, degradation should not only be considered as a negative 
phenomenon, as low molecular weight peptides formed during ECM degradation may 
have a chemo-attractant potential for several cell types (Badylak & Gilbert, 2008). It is thus 
the degradation rate of the scaffold that should be primarily considered and evaluated. 
Depending on the application and cells involved, the degradation rate has to be 
investigated to ensure proper host cell recruitment and tissue remodelling. The pathways 
of the immune response involved in this process remain to be fully described (Badylak & 
Gilbert, 2008). 
Introducing cross-links between the polypeptide chains of the ECM has been shown to 
reduce immunogenicity of the pericardium (Mirsadrae et al., 2007) as well as its 
biodegradability (Taylor et al., 2006) by increasing its resistance to enzymatic degradation. 
Until now, glutaraldehyde (GA)-fixed bovine pericardium has been preferred as a substitute 
to autologous human pericardium. GA was first introduced by Carpentier et al. (Carpentier 
et al., 1969) as a cross-linking reagent to chemically modify the collagen and render the 
tissue immunologically acceptable in the human host. Fixation was shown to increase 
stability and strength of the pericardium (Jayakrishnan & Jameela, 1996). GA remains the 
gold standard as a cross-linking reagent despite its well-known drawbacks. Indeed, GA has 
been reported to accelerate the calcification process, which considerably limits its 
application. Calcification is thus the main cause of long-term failure of GA-fixed pericardial 
valves (Gallo et al., 1985; Grabenwoger et al., 1996). Furthermore, a GA-treated pericardium 
has a poor ability to regenerate in vivo due to the cross-linking of the tissue. Moreover GA 
residues display cytotoxic effects preventing host cell attachment, migration and 
proliferation (Huang-Lee et al., 1990). 
It is now accepted that GA cross-linking increases tissue stiffness (Thubrikar et al., 1983) 
with the possibility of tissue buckling (Vesely et al., 1988). Standard use of GA cross-linking 
leads to a high risk of calcific degeneration as well as tissue fatigue (Grabenwoger et al., 
1992). This is mostly due to inflammatory and cytotoxicity changes (Huang Lee et al., 1990), 
and continuous wear and tear leading to collagen fiber fragmentation. 
Besides glutaraldehyde, several cross-linking compounds have been reported in the 
literature such as genipin (Wei et al., 2005) or epoxy compound (Sung et al., 1997). These 
alternative methods are used to bridge hydroxylysine residues of different polypeptide 
chains or amino groups of lysine by oligomeric or monomeric crosslinks (Sung et al., 2003). 
Because of the adverse effects of cross-linking with glutaraldehyde or other aldehyde 
treatments such as formaldehyde (Nimni et al., 1988) or dialdehyde starch (Rosenberg, 
1978), numerous non-aldehyde treatments have been proposed, such as carbodiimides 
(Sung et al., 2003), glycerol (Ferrans et al., 1991), glycidal ethers (Thyagarajanet al., 1992) 
including poly(glycidylether) (Noishiki et al., 1986), acyl azide (Petite et al., 1990), cyanimide 
(Pereira et al., 1990), genipin (Wei et al., 2005), or dye-mediated photo-oxidation, phytate 
(Grases et al., 2008).  
Genipin, obtained from the fruits of Gardenia jasminoides ELLIS (Fujikawa et al., 1987; Tsai et 
al., 1994), exhibited better results than glutaraldehyde regarding its cytotoxicity (Sung et al., 
1999), inflammatory response, ability to prevent calcification and tissue-induced mechanical 
properties (Wei et al., 2005). Epoxy compound, initially proposed by Noishiki et al. (Noishiki 
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et al., 1989), was shown to be less cytotoxic, superior in pliability and to better inhibit 
calcification than glutaraldehyde (Sung et al., 1997). 
Carbodiimides generate amide-type crosslinks via direct cross-linking of the polypeptide 
chains. Use of carbodiimide cross-linking leads to the activation of the carboxylic acid 
groups of glutamic or aspartic acid residues to obtain O-acylisourea groups. Hydroxyline 
residues or free amino groups of lysine generate a nucleophilic attack which allows cross-
link formation (Timkovich, 1977). It was noted that adding N-hydroxysuccinimides to 
carbodiimides considerably increases cross-link number (Olde Damink et al., 1996). In 
addition, the use of carbodiimides displayed increased stability towards enzymatic 
degradation on collagen-based tissue such as pericardium (Sung et al., 2003). 
Glutaraldehyde acetal cross-linking reagent has been developed with glutaraldehyde in acid 
ethanolic solution (Yoshioka & Goissis, 2008), protecting free aldehydic reactive groups and 
minimizing the polymeric formation of glutaraldehyde. This reduces superficial effects with 
glutaraldehyde cross-linking on pericardial tissue. 
Crosslinking of the pericardial tissue with a dye-mediated photo-oxydation process 
provides chemical, enzymatic and in vivo stability as well as biomechanical integrity of the 
treated tissue (Moore et al., 1994). Penta-golloyl glucose, a collagen-binding polyphenol, 
stabilizes collagen, preventing its degradation, and allows progressive host cell infiltration 
as well as ECM remodeling. An in vivo study has shown that porcine pericardium does not 
calcify with such treatment at 6 weeks when implanted subdermally in rats (Tedder et al., 
2008). Reuterin, an antimicotic and antibacterial compound obtained from Lactobacillus 
reuteri (Axelsson et al., 1989), has been studied as a crosslinking reagent (Chen et al., 2002). It 
is a three-carbon aldehyde reacting, as formaldehyde, with free amino groups. Reuterin 
cross-linked pericardium exhibits comparable results to glutaraldehyde in terms of 
resistance against enzymatic degradation, denaturation temperature and free amino group 
content, while decreasing cytotoxic effects (Chen et al., 2002). Tannic acid has been studied 
on pericardial tissue and was shown to crosslink proteins by creating multiple hydrogen 
bonds due to its hydroxyl groups (Cwalina et al., 2005; Jastrzebska et al., 2006). It exerts an 
anti-inflammatory effect, especially on macrophages, as well as an anti-calcification effect on 
glutaraldehyde-fixed bovine pericardium (Wang et al., 2008). Proanthocyanidin, a natural 
crosslinking reagent with polyphenolic structures, has the potential to create a stable 
hydrogen-bonded structure and to increase collagen synthesis, generating 
nonbiodegradable collagen matrices (Han et al., 2003). Proanthocyanidin-treated pericardial 
tissues are non-cytotoxic and resist against enzyme digestion, and have been shown to be 
compatible with cell attachment and proliferation. Phytate has been suggested as an anti-
calcification reagent (Grases et al., 2006, 2008) and has achieved promising results, to be 
validated by further studies. Other amide-type crosslinks, based on the activation of 
carboxyl groups, have been studied, such as diphenylphosphorylazide or 
ethyldimethylaminopropyl carbodiimide. It appears, according to Jorge-Herrero et al., that 
these two chemical treatments are not a good alternative compared to glutaraldehyde. 
Indeed, pericardial tissues treated with those reagents are less resistant to calcifications and 
proteolytic attacks (Jorge-Herrero et al., 1999). 
Numerous alternative treatments to glutaraldehyde cross-linking have been developed and 
investigated over the years. However, most of them were mainly evaluated in vitro and 
compared only to glutaraldehyde. A comprehensive comparative study of the different 
reagents remains to be conducted in terms of benefits regarding the tissue properties as well 
as their potential toxicity or deleterious effects.  
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4.2 Coating of the pericardium 
Another possible post-decellularization treatment resides in the coating of the bioprosthesis. 
This procedure should allow improvement of graft integration at the site of implantation as 
well as decreasing degradation of the pericardial tissue.  
Coating bovine pericardium with biopolymeric films, either chitosan or silk fibroin, has 
been investigated by Nogueira et al. (Nogueira et al., 2010). These methods are interesting 
approaches and both treatments appear to be non-cytotoxic. Nevertheless, chitosan does not 
allow endothelialisation and silk fibroin-coated bovine pericardium calcifies in vivo. Further 
investigation has to be performed to tackle these major concerns. 
In their study, Dong et al. suggested treating bovine pericardium with acetic acid coupled 
with RGD polypeptides (Dong et al., 2009). Acetic acid increases pericardial scaffold pore 
size and porosity while RGD peptides is meant to improve cell adhesion and growth. 
Hence, RGD polypeptides have been identified in fibronectin (Pierschbacher & Ruoslahti, 
1984), collagen, vitronectin and membrane proteins (Ruoslahti & Pierschbacher, 1987). These 
sequences have an impact on integrins, which display cell adhesion receptor roles 
controlling cell signaling pathways. 
4.3 Pericardium anti-calcification treatments 
The mechanism of calcification on glutaraldehyde-treated pericardium is not well 
understood because of its complexity. Nevertheless, there is evidence that pericardial tissue 
residual antigens, free aldhehyde groups of glutaraldehyde and phospholipids are involved 
in this mechanism. 
Thus, circulating antibodies can contribute to pericardial calcification due to a possible 
immune response. Free aldehyde groups of glutaraldehyde can attract host plasma calcium, 
increasing tissue calcification. Phospholipids may bind calcium and play an important role 
in the calcium phosphate crystal formation. Several strategies have been investigated to 
tackle these major issues. 
Suppression of residual antigenicity has been proposed to prevent calcification and it has 
been shown to be effective. This was performed by fixation treatments using a broad range 
of high concentrations of glutaraldehyde (Trantina-Yates et al., 2003; Zilla et al., 2000). To 
remove free aldehyde groups, a large number of amino acids or amino compounds were 
studied. Post-fixation treatments with amino acids displayed an improved spontaneous 
endothelialisation in vivo of glutaraldehyde-fixed bovine pericardium (Moritz et al., 1991; 
Jorge-Herrero et al., 1996). The use of L-glutamic acid did reduce residual and unbound 
aldehyde groups, on glutaraldehyde-fixed bovine pericardium and significantly decreased 
the risk of calcification (Grimm et al., 1991; Leukauf et al., 1993). Post-treatment with L-
arginine also resulted in decreased calcium deposition (Jee et al., 2003). Recently, Lee et al. 
proposed a post-fixation treatment with glycine (Lee et al., 2010). Early results are promising 
but require further investigation on larger studies.  
Alcohol solutions, including ethanol, have been investigated as a treatment to remove tissue 
phospholipids, thus preventing calcification (Pathak et al., 2004; Vyavahare et al., 1998). 
Besides, other techniques have been proposed to minimize the side effects of glutaraldehyde 
residues on GA-treated pericardium. Lyophilization has been shown to decrease aldehyde 
residues, decreasing the risk of calcification and cytotoxicity (Santibáñez-Salgado et al., 2010). 
Moreover, treatments with heparin or sulphonated poly(ethylene oxide) following 
glutaraldehyde pre-treatment have been proposed (Lee et al., 2000, 2001). Both methods block 
side effects of GA residues and thus prevent calcification of the pericardium. Finally, a 
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modified adipic dihydrazide hyaluronic acid has been proposed to be grafted on to 
glutaraldehyde-treated bovine pericardium (Ohri et al., 2004). Calcifications decreased 
considerably with this post-treatment compared to the control group at two weeks following a 
subcutaneous implantation in mice. 
5. Applications of the pericardium as a biomaterial 
So far, the pericardium has been mostly used for cardio-vascular applications, i.e. vascular 
grafts (Schmidt & Baier, 2000; Chvapil et al., 1970; Matsagas et al., 2006; Menasche et al.,  
 
Pericardium 
source 
Surgical fields Product Company 
Bovine or 
porcine 
Soft tissue repair  
Hernia repair  
Abdominal & thoracic 
wall defects 
-Peripatch Implantable 
surgical tissue  
-TutoMesh 
Neovasc,  
Maverick Biosciences PTY Limited, 
Tutogen medical GmbH, RTI Biologics,  
Med&Care,  
Biovascular Inc, 
Novomedics 
Strip reinforcement -Veritas Peristrips Dry Synovis Life Technology 
Orbital repair -Tutopatch 
-Ocugard 
Tutogen medical GmbH, RTI Biologics,  
Med&Care,  
Biovascular Inc, 
Novomedics 
Dural repair -Lyolem r All BP National tissue Bank Malaysia 
Perivascular Patch -Peripatch biologic 
vascular patch 
Neovac 
Cardiac reconstruction 
and repair 
-Peripatch Implantable 
Surgical Tissue 
Neovasc, Maverick Biosciences PTY 
Limited 
Heart valve 
replacement 
-PercevalS aortic valve 
-Mitroflow pericardial 
aortic valve 
-Freedom solo  
-Carpentier-Edwards 
PERIMOUNT Magna 
EaseAortic Heart Valve 
-Carpentier-Edwards 
PERIMOUNT Magna 
Mitral Ease Heart Valve 
-Carpentier-Edwards 
PERIMOUNT Theon 
Aortic Heart Valve 
-Carpentier-Edwards 
PERIMOUNT Theon 
Mitral Replacement 
System 
Sorin group 
“ 
“ 
Edwards Life Sciences 
 
 
“ 
 
 
“ 
 
“ 
Equine Tendon repair -OrthADAPT Synovis Life Technologies Inc 
Human 
Valvuloplasty 
Heart valve 
-Xeno or (tissue bank) or 
autologous grafts 
Lausberg et al, 2006 
Mirsadaee et al, 2006 
Table 2. Applications of pericardium as medical devices. 
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1984; Moon & West; 2008), and heart valves (Ishihara et al., 1981; Schoen & Levy, 1999; 
Flanagan & Pandit, 2003; Vesely, 2005). Pericardial bioprostheses have also been described 
for the treatment of acquired cardiac pathologies, including postinfarction septal defects 
(David et al., 1995), reconstruction of mitral valve annulus (David et al., 1995a, 1995b) or 
outflow obstruction (Sommers & David, 1997). 
Additionally, pericardium has also been used for the construction of bioprostheses in non-
cardiac treatments such as patches for vaginal (Lazarou et al., 2005) or abdominal wall 
reparation (Limpert et al., 2009), dural repair (Cantore et al., 1987) or tracheoplasty (Dunham 
et al., 1994). 
6. Conclusion 
For clinical application, pericardial tissue has to be decellularized to prevent an immune 
responses or immune-mediated rejection of the pericardium. Various decellularization 
protocols have been largely reviewed here. The choice of the decellularization strategy has an 
impact on the mechanical properties, the scaffold pore size, the scaffold tissue integration and 
the development of long-term calcification. All these considerations should be carefully taken 
into account when designing new pericardial-based biomaterials. Currently, glutaraldehyde 
is the gold standard for pericardial treatment used in clinical practice. Nevertheless, it has 
important drawbacks including cytotoxic effects, prevention of host cell attachment, 
migration and proliferation (Huang-Lee et al., 1990), and a high propensity to calcify. 
Alternative treatments to replace or complement glutaraldehyde crosslinking of the 
pericardium have been investigated using other crosslinking reagents, decellularization, 
lyophilisation or coating with biopolymers (Nogueira et al., 2010). Despite many studies, it is 
still difficult to know which strategy to adopt regarding pericardial treatment. First, we do 
not have enough follow-up to permit evaluation of most of these alternatives and treatments. 
Second, every new treatment proposed is generally compared only to glutaraldehyde. It is 
thus not possible to classify these treatments by efficiency. Finally, the protocol for an optimal 
treatment depends largely on the final application targeted. In addition, there have been 
recent advances in tissue regeneration with the emergence of cell therapy and new 
pericardial treatments with cellular growth factors promoting recellularization (Chang et al., 
2007). However, further improvements need to be achieved to transform these techniques 
into clinical applications. The use of autologous pericardium in cardiac valvular therapy is 
also a challenging alternative. Nevertheless, it still currently requires the development of 
local pericardial treatments aiming to favor the valvular remodelling. The understanding of 
current issues and the improvement of pericardial processing may have a huge impact for 
bioprothesis conception and patient safety. 
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